Carl Zeiss Meditec : Q1 due 11 Feb - A solid quarter expected
>Q1 solid, but also impacted by supply constraints - While estimating sales growth of c. 9% y-o-y excl. forex for FY 2021-22 - on the back of expecting the world going back to normal -, we forecast +7% y-o-y for Q1. This is largely due to supply chain constraints holding back a more vibrant recovery (order book estimated to cover more than one quarter). We do not think the Omicron wave will have a profound negative effect on the company’s business. As we also do ...Carl Zeiss Meditec is a holding company. Co.'s businesses are focused on two primary areas: Ophthalmology and Microsurgery. In Ophthalmology, Co.'s operations are divided in to two strategic business units: Ophthalmic Systems, which includes a range of laser and diagnostic systems for ophthalmology; and Surgical Ophthalmology, which consists of activities in the field of ophthalmic implants and consumables. In Microsurgery, Co. provides surgical microscopes and visualization solutions, e. g. for ear, nose and throat surgery, or neurosurgery. These products are mainly used to assist with the removal of tumors, as well as the treatment of vascular diseases and functional disorders.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.